Last reviewed · How we verify
NCT00917202
Efficacy of Methylene Blue for Malaria Treatment in Adults of Burkina Faso: Proof of Principle Study in Semi-Immune Adults of Burkina Faso in the Frame of the A8
Phase 2 trial testing Methylenblue in Malaria. Completed.
Quick facts
| Lead sponsor | Heidelberg University |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Sites | 1 location across Burkina Faso |
Drugs / interventions tested
- Methylenblue — full drug profile →
Conditions studied
- Malaria — all drugs for Malaria →
Sponsor
Heidelberg University
Who can join
Adults 17 to 55, male only, with Malaria.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
- Adequate clinical and parasitolgical response (ACPR) until D 28
Sponsor's own description
Design: Single-centre, controlled study in adults with uncomplicated falciparum malaria in the Nouna Health District, north-western Burkina Faso Phase: Phase II Objectives: The primary objective of this trial is to study the efficacy of different methylene blue regimens given to adults with uncomplicated falciparum malaria in an African area of high malaria transmission intensity. Population: Male adults with uncomplicated malaria from Nouna town. Sample size: N= 60 (n=20 for each group; three different dosing regimens of MB). Treatment: The participants in the three different MB regimens will receive orally twice daily 390 mg MB (total daily dose 780mg) over 7,5 or 3 days respectively. Treatment with the five (three) day regimen will only start after all patients of the seven (five) days regimen have been followed up until day 3. Endpoints: The primary endpoint is the adequate clinical and parasitological response (ACPR) rate on day 28. Secondary endpoints are the number of adverse events (AE) after drug intake until day 28, clinical and parasitological failure rates on day 14 and 28, changes in haemoglobin/haematocrit until day 28, and fever and parasite clearance time.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Beyond the margins: real-time detection of cancer using targeted fluorophores.
Zhang RR, Schroeder AB, Grudzinski JJ, Rosenthal EL, et al · · 2017 · cited 321× · PMID 28094261 · DOI 10.1038/nrclinonc.2016.212
Verify or expand the search:
- PubMed search for NCT00917202
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Malaria
Currently open trials in the same condition.
- NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
- NCT07036159 — A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months · Phase 2 · recruiting
- NCT06735209 — First-in-Human PfSPZ-LARC2 Vaccination/CHMI · Phase 1 · active not recruiting
- NCT06854042 — A Study of Oral E1018 in Healthy Adult Participants · Phase 1 · recruiting
- NCT06607003 — Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Cha · Phase 1 · recruiting
Other Heidelberg University trials
Trials by the same sponsor.
- NCT07106294 — Hyperspectral Imaging for Prediction of Preeclampsia · recruiting
- NCT06651164 — Psychosomatic Risk Screening · NA · completed
- NCT07378345 — Optimization of Communication Between Surgery and Pathology · NA · completed
- NCT06018272 — Mentalization-based Treatment Versus Bona-fide Treatment for Patients With Borderline Personality Disorder in Germany · NA · recruiting
- NCT06852599 — Long-term Outcomes of Implants in Patients with Periodontitis · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00917202 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Heidelberg University
- Last refreshed: 9 June 2009
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00917202.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing